Mindset Pharma Inc., a drug discovery company dedicated to developing novel, optimized medications to address neuropsychiatric and neurological disorders with unmet medical needs, has filed two international patent applications under the Patent Coorperation Treaty for the protection of its non-hallucinogenic Family 6 compounds.
The filings are based on pre-clinical studies and provide Mindset with the preliminary freedom to operate for all claimed drug candidates from Family 6. This marks an exciting step forward for the company, as it looks to bring these potentially life-changing medications to market.
Mindset Pharma is revolutionizing the drug discovery and development process with its innovative platform, which has yielded promising results with its novel psychedelic-inspired non-hallucinogenic drug candidates.
This new class of drugs may offer a wider range of potential treatments, including for children and geriatric patients, without requiring in-clinic supervision. This could result in reduced costs and improved convenience for patients seeking these treatments. According to CEO James Lanthier, “We are excited to be leading the way in this groundbreaking field.”
The pre-clinical study results supporting the discovery of the novel non-tryptamine psychedelic-inspired compounds have been highly encouraging. In-vitro screening, ADME (absorption, distribution, metabolism, and excretion), along with in vivo studies, have indicated that these compounds exhibit 5-HT2A serotonin receptor activation without the associated hallucinogenic effects.
While some compounds are more potent than psilocybin and 5-MeO-DMT as 5-HT2A agonists, their activation of the head twitch response has been minimal or non-existent, suggesting a non-hallucinogenic profile. We are thrilled to share our progress on these promising drug candidates and look forward to their continued development.
About Mindset Pharma Inc.
Mindset Pharma Inc. is a pioneering drug discovery and development company that is revolutionizing the therapeutic potential of psychedelic drugs to treat neurological and psychiatric disorders with unmet needs.
By creating optimized and patentable best-in-class innovative next-generation psychedelic medicines, Mindset is leading the way towards a new era of psychedelic-based treatments. The company is developing multiple novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybins, in addition to its own proprietary compounds.
In addition, Mindset has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, to help bring these groundbreaking treatments to the public.